3月14日,西藏药业(600211)发布公告,关于与康哲药业控股有限公司下属公司的日常关联交易预计情况。公司预计2025年度的推广费用及奖励金将不超过17.8亿元,而2024年度实际发生的推广费用为14.79亿元,预计金额与实际金额存在差异的主要原因是产品销售收入受市场需求等多种因素影响。2025年度,双方仍将维持合作关系,并继续由康哲药业下属公司负责产品的市场推广。预计2025年度的推广保证...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.